Cigna Switch Program Intensifies Competitive Dynamics For Cosentyx
Executive Summary
A new pilot program by the insurer is offering a $500 debit card to patients who switch from the blockbuster Novartis psoriasis drug to Lilly's rival Taltz or other preferred drugs.
You may also be interested in...
COVID-19 Hit New Medication Starts Across Broad Therapeutic Areas
Categories from asthma to high blood pressure to cancer showed reductions in new medication users in 2020, likely caused by fewer new diagnoses because of the pandemic, a report from Cigna’s Evernorth shows.
Specialty Drugs Outweighed Traditional Drug Spending For The First Time
Drugs for inflammatory conditions and cancer drove the increase in spending among the pharmacy benefit manager’s commercial plans, according to a drug trend report from Cigna's Evernorth.
Lilly’s Bio-Medicines Portfolio Grows To Offset Pressures In Key Markets
Lilly Bio-Medicines president Ilya Yuffa oversees newer products in competitive therapeutic areas and drug classes, but additional indications and new therapies within the group’s immunology, pain and neuroscience focus areas will capitalize on the group’s existing commercial expertise.